Cargando…

Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience

Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thir...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, QingYun, Ren, HanYun, Liang, ZeYin, Liu, Wei, Yin, Yue, Wang, QingYa, Wang, Qian, Sun, YuHua, Xu, WeiLin, Qiu, ZhiXiang, Ou, JinPing, Han, Na, Wang, Jing, Dong, YuJun, Li, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820587/
https://www.ncbi.nlm.nih.gov/pubmed/35141252
http://dx.doi.org/10.3389/fmed.2021.807527
_version_ 1784646234308345856
author Wang, QingYun
Ren, HanYun
Liang, ZeYin
Liu, Wei
Yin, Yue
Wang, QingYa
Wang, Qian
Sun, YuHua
Xu, WeiLin
Qiu, ZhiXiang
Ou, JinPing
Han, Na
Wang, Jing
Dong, YuJun
Li, Yuan
author_facet Wang, QingYun
Ren, HanYun
Liang, ZeYin
Liu, Wei
Yin, Yue
Wang, QingYa
Wang, Qian
Sun, YuHua
Xu, WeiLin
Qiu, ZhiXiang
Ou, JinPing
Han, Na
Wang, Jing
Dong, YuJun
Li, Yuan
author_sort Wang, QingYun
collection PubMed
description Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thirty consecutive patients were enrolled in the study with a median follow-up of 50 months (range 4, 141), and the median age of the patients was 21 years (range 3, 49). All the patients achieved myeloid engraftment in the two cohorts. The cumulative incidences of platelet engraftment were 95.5 and 100% in HID cohort and MSD cohort, respectively. The median time for neutrophil and platelet recovery was 11 (range 9, 19) and 15 (range 10, 25) days in HID cohort, and 12 (range 10, 19) and 14 (range 8, 25) days in MSD cohort. The cumulative incidences of grade II–IV and grade III–IV acute graft vs. host disease (aGvHD) in HID cohort and in MSD cohort were 18.9 vs. 14.3% (p = 0.77) and 10.5 vs. 0% (p = 0.42), respectively. The cumulative incidences of chronic graft vs. host disease (cGvHD) was 22.7% in HID cohort and 25.5% in MSD cohort (p = 0.868). The 5-year overall survival (OS) rates and 5-year failure-free survival (FFS) rates in HID cohort and MSD cohort were 85.1 vs. 87.5% (p = 0.858), 80.3 vs. 87.5% (p = 0.635), respectively. The median time to achieve engraftment, cumulative incidence of aGvHD and cGvHD, and the 5-year OS and FFS rates were not significantly different between the two cohorts. We suggest that HID-HSCT might be a safety and effective option for SAA patients without a matched donor.
format Online
Article
Text
id pubmed-8820587
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88205872022-02-08 Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience Wang, QingYun Ren, HanYun Liang, ZeYin Liu, Wei Yin, Yue Wang, QingYa Wang, Qian Sun, YuHua Xu, WeiLin Qiu, ZhiXiang Ou, JinPing Han, Na Wang, Jing Dong, YuJun Li, Yuan Front Med (Lausanne) Medicine Clinical data of patients with severe aplastic anemia (SAA) were retrospectively analyzed to evaluate the outcomes of haploidentical hematopoietic stem cell transplantation (HID-HSCT) with matched related sibling hematopoietic stem cell transplantation (MSD-HSCT) in complications and survivals. Thirty consecutive patients were enrolled in the study with a median follow-up of 50 months (range 4, 141), and the median age of the patients was 21 years (range 3, 49). All the patients achieved myeloid engraftment in the two cohorts. The cumulative incidences of platelet engraftment were 95.5 and 100% in HID cohort and MSD cohort, respectively. The median time for neutrophil and platelet recovery was 11 (range 9, 19) and 15 (range 10, 25) days in HID cohort, and 12 (range 10, 19) and 14 (range 8, 25) days in MSD cohort. The cumulative incidences of grade II–IV and grade III–IV acute graft vs. host disease (aGvHD) in HID cohort and in MSD cohort were 18.9 vs. 14.3% (p = 0.77) and 10.5 vs. 0% (p = 0.42), respectively. The cumulative incidences of chronic graft vs. host disease (cGvHD) was 22.7% in HID cohort and 25.5% in MSD cohort (p = 0.868). The 5-year overall survival (OS) rates and 5-year failure-free survival (FFS) rates in HID cohort and MSD cohort were 85.1 vs. 87.5% (p = 0.858), 80.3 vs. 87.5% (p = 0.635), respectively. The median time to achieve engraftment, cumulative incidence of aGvHD and cGvHD, and the 5-year OS and FFS rates were not significantly different between the two cohorts. We suggest that HID-HSCT might be a safety and effective option for SAA patients without a matched donor. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8820587/ /pubmed/35141252 http://dx.doi.org/10.3389/fmed.2021.807527 Text en Copyright © 2022 Wang, Ren, Liang, Liu, Yin, Wang, Wang, Sun, Xu, Qiu, Ou, Han, Wang, Dong and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Wang, QingYun
Ren, HanYun
Liang, ZeYin
Liu, Wei
Yin, Yue
Wang, QingYa
Wang, Qian
Sun, YuHua
Xu, WeiLin
Qiu, ZhiXiang
Ou, JinPing
Han, Na
Wang, Jing
Dong, YuJun
Li, Yuan
Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title_full Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title_fullStr Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title_full_unstemmed Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title_short Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience
title_sort comparable outcomes in acquired severe aplastic anemia patients with haploidentical donor or matched related donor transplantation: a retrospective single-center experience
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820587/
https://www.ncbi.nlm.nih.gov/pubmed/35141252
http://dx.doi.org/10.3389/fmed.2021.807527
work_keys_str_mv AT wangqingyun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT renhanyun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT liangzeyin comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT liuwei comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT yinyue comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT wangqingya comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT wangqian comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT sunyuhua comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT xuweilin comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT qiuzhixiang comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT oujinping comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT hanna comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT wangjing comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT dongyujun comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience
AT liyuan comparableoutcomesinacquiredsevereaplasticanemiapatientswithhaploidenticaldonorormatchedrelateddonortransplantationaretrospectivesinglecenterexperience